Search Results

Search Results for "transvaginal mesh"

• J&J seeks priority review for new drug
  The U.S. Food and Drug Administration intends to give priority review to Johnson & Johnson’s experimental treatment for multidrug-resistant tuberculosis. According to a story in the Newark Star Ledger, Johnson & Johnson’s Janssen Research & Development unit applied for approval to ma...

• Court refuses to throw out J&J fine
  According to Bloomberg, a Louisiana appeals court declined to throw out an award of nearly $258 million that Johnson & Johnson must pay to state officials, over illegal marketing of its antipsychotic drug Risperdal. Jurors in Louisiana found Johnson & Johnson officials violated the state’s...

• Troubled J&J appoints new executive
  According to a story in the Boston Globe, Johnson & Johnson has appointed Bayer executive Sandra E. Peterson to oversee the company’s troubled consumer health and manufacturing operations. The move is an attempt by Alex Gorsky, who became CEO of Johnson & Johnson in April, to address a hos...

• J&J settles Risperdal lawsuit on first day of trial
  On the first day of trial, Johnson & Johnson settled a lawsuit centering on complaints that its antipsychotic drug Risperdal caused a male plaintiff to grow breasts, Bloomberg reports. The terms of the settlement are confidential. It was the first of about 130 lawsuits alleging that Risperdal ca...

• Public demands forced corporate changes
  An opinion piece for the Boston Globe points out that public scrutiny and consumer activism is what prompted Johnson & Johnson’s recent decision to phase out questionable chemicals in its full line of products. The piece applauds that decision, and urges members of the public to keep up that k...

• FDA rushing J&J application
  The U.S. Food and Drug Administration has agreed to give priority review status to Johnson & Johnson’s application for a new usage of its prostate cancer treatment Zytiga, Reuters reports. That means the drug will be reviewed faster than usual. The priority review status is granted by the FDA ...

• Lawsuit filed against J&J over misleading claims
  Consumer advocacy group Center for Science in the Public Interest has filed a federal lawsuit over artificial sweetener Splenda Essentials, claiming that Johnson & Johnson subsidiary McNeil Nutritionals is misleading consumers about the product’s supposed health benefits. In a press release, C...

• Government launches more inquiries into J&J
  Even as Johnson & Johnson is settling previous charges that may cost about $2.2 billion, the government is making new inquiries into allegations that the company used illegal tactics to promote and market its drugs, the Wall Street Journal reports. According to the Wall Street Journal, the U.S. ...

• Despite problems, Johnson & Johnson making money
  The investment blog Seeking Alpha says Johnson & Johnson is doing quite well financially despite its recent problems – including high-profile and costly recalls of faulty medical devices. The report notes that Warren Buffett’s Berkshire Hathaway Inc. dropped two-thirds of its holdings in the...

• J&J to pay $181 million in illegal marketing settlement
  Johnson & Johnson will pay 36 states and the District of Columbia $181 million as a settlement for allegations that the company inappropriately marketed its antipsychotic drug Risperdal, the Philadelphia Inquirer reports. Federal and state investigators have been examining the company’s Ri...